Oncolytics Biotech Files 6-K
Ticker: ONCY · Form: 6-K · Filed: Sep 29, 2025 · CIK: 1129928
Sentiment: neutral
Topics: reporting-status, foreign-private-issuer, sec-filing
Related Tickers: ONCY
TL;DR
ONCOLYTICS BIOTECH (ONCY) filed a 6-K, confirming foreign private issuer status and 20-F filing.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on September 29, 2025, reporting as a foreign private issuer. The company, based in Calgary, Alberta, Canada, is a pharmaceutical preparations company and will file its annual reports under Form 20-F.
Why It Matters
This filing indicates Oncolytics Biotech Inc. is a foreign private issuer and will be filing its annual reports on Form 20-F, which is standard for non-US companies.
Risk Assessment
Risk Level: low — This is a routine administrative filing confirming the company's reporting status.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — Registrant
- September 2025 (date) — Reporting period
- 20250929 (date) — Filing date
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed by Oncolytics Biotech Inc. for the month of September 2025.
Which annual report form will Oncolytics Biotech Inc. file?
Oncolytics Biotech Inc. will file its annual reports under cover of Form 20-F.
Where is Oncolytics Biotech Inc. located?
Oncolytics Biotech Inc. is located in Calgary, Alberta, Canada.
What is the Commission File Number for Oncolytics Biotech Inc.?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512.
What is the SIC code for Oncolytics Biotech Inc.?
The Standard Industrial Classification (SIC) code for Oncolytics Biotech Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2025-09-29 09:08:06
Filing Documents
- form6kpdacregupdate.htm (6-K) — 17KB
- padcregupdate.htm (EX-99.1) — 14KB
- 0001129928-25-000079.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date September 29, 2025 Kirk Look Chief Financial Officer